Latest News
Is Novavax Stock a Buy?
Can Novavax's stock continue soaring?
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths...
If You'd Invested $10,000 in Novavax a Year Ago, This Is How Much You'd Have Now
This coronavirus vaccine maker entered the market behind rivals.
1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell?
A potentially very lucrative arrangement with a peer doesn't necessarily make the company a buy.
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now
These two healthcare stocks may be deeply undervalued.
Novavax Stock Just Tripled. Is It Too Late to Buy?
Novavax shares have soared and plummeted in recent years.
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?
Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.
Why Novavax Stock More Than Doubled Today
A cloud of doubt hanging over the company just gave way to some sunshine.
Sanofi will take a 4.9% stake in the U.S. drugmaker for $70-million. That values Novavax at about $1.4-billion, nearly double its market capitalization of about $628-million as of Thursday
June S&P 500 E-Mini futures (ESM24) are up +0.40%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.44% this morning after three major U.S. benchmark indices ended the regular session in the green as higher-than-expected applications for U.S. unemployment benefits bolstered the case for rate cuts, with investors looking ahead to fresh comments from Federal Reserve officials.
Forget Nvidia: These 3 Small-Cap Stocks Offer Up to 557% Upside, According to Select Wall Street Analysts
High-water price targets from a trio of Wall Street pundits imply three diminutive companies can skyrocket 223% to 557%.
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
These stocks aren't bargains.
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Catalysts lie ahead for both of these companies.
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs?
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?
Is there still too much risk surrounding this business?
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague
These stocks could move in very different directions over the long run.
1 Beaten-Down Stock That's Still Not Worth Buying
For this biotech, a rebound seems far too unlikely.
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street
Could these biotech companies still win in the vaccine market and beyond?
Is Novavax a Buy Now?
The stock has dropped 98% over the past three years.
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Can the stock's recent rally continue?
Has Novavax Just Solved Its Biggest Problem?
The biotech company recently settled a dispute with a major customer.
Better Bull Market Buy: Novavax vs. Pfizer
Bull markets usually favor stocks with promising growth prospects.
Where Will Novavax Be in 10 Years?
Without any windfalls on the horizon, times are dire for this biotech.
3 Beaten-Down Growth Stocks that Could Take off in the New Bull Market
Bull markets favor growth stocks so now could be the time for these players to shine.
Better Recovery Story Buy: Novavax vs. Teladoc
Both stocks have fallen more than 90% from their peak.